

Elena Boggio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8473987/publications.pdf>

Version: 2024-02-01

44
papers

1,222
citations

304743

22
h-index

377865

34
g-index

44
all docs

44
docs citations

44
times ranked

2041
citing authors

#	ARTICLE	IF	CITATIONS
1	Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases. <i>Journal of Immunology Research</i> , 2016, 2016, 1-15.	2.2	120
2	Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis. <i>Vaccine</i> , 2014, 32, 5681-5689.	3.8	116
3	<i>In Vitro&/i> and <i>In Vivo&/i> Therapeutic Evaluation of Camptothecin-Encapsulated <i>P&/i>-Cyclodextrin Nanosponges in Prostate Cancer. <i>Journal of Biomedical Nanotechnology</i> , 2016, 12, 114-127.	1.1	67
4	Serum levels of osteopontin are increased in SIRS and sepsis. <i>Intensive Care Medicine</i> , 2008, 34, 2176-2184.	8.2	60
5	Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 255.	4.1	56
6	Improvement in the Anti-Tumor Efficacy of Doxorubicin Nanosponges in In Vitro and in Mice Bearing Breast Tumor Models. <i>Cancers</i> , 2020, 12, 162.	3.7	47
7	Development and Characterization of Solid Lipid Nanoparticles Loaded with a Highly Active Doxorubicin Derivative. <i>Nanomaterials</i> , 2018, 8, 110.	4.1	46
8	Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells <i>in vitro&/i> and <i>in vivo&/i> on orthotopic xenograft tumors. <i>Drug Delivery</i> , 2017, 24, 670-680.	5.7	41
9	B7h Triggering Inhibits the Migration of Tumor Cell Lines. <i>Journal of Immunology</i> , 2014, 192, 4921-4931.	0.8	40
10	Thrombin Cleavage of Osteopontin Modulates Its Activities in Human Cells<i> In Vitro&/i>and Mouse Experimental Autoimmune Encephalomyelitis<i> In Vivo&/i>. <i>Journal of Immunology Research</i> , 2016, 2016, 1-13.	2.2	40
11	Variations of the perforin gene in patients with multiple sclerosis. <i>Genes and Immunity</i> , 2008, 9, 438-444.	4.1	39
12	Osteopontin binds ICOSL promoting tumor metastasis. <i>Communications Biology</i> , 2020, 3, 615.	4.4	39
13	Paclitaxel-Loaded Nanosponges Inhibit Growth and Angiogenesis in Melanoma Cell Models. <i>Frontiers in Pharmacology</i> , 2019, 10, 776.	3.5	36
14	Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. <i>Scientific Reports</i> , 2017, 7, 43718.	3.3	35
15	ICOS-Ligand Triggering Impairs Osteoclast Differentiation and Function In Vitro and In Vivo. <i>Journal of Immunology</i> , 2016, 197, 3905-3916.	0.8	34
16	IL-17 protects T cells from apoptosis and contributes to development of ALPS-like phenotypes. <i>Blood</i> , 2014, 123, 1178-1186.	1.4	30
17	Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. <i>Frontiers in Immunology</i> , 2017, 8, 321.	4.8	30
18	Immunotherapy of experimental melanoma with ICOS-Fc loaded in biocompatible and biodegradable nanoparticles. <i>Journal of Controlled Release</i> , 2020, 320, 112-124.	9.9	30

#	ARTICLE	IF	CITATIONS
19	Triggering of B7h by the ICOS Modulates Maturation and Migration of Monocyte-Derived Dendritic Cells. <i>Journal of Immunology</i> , 2013, 190, 1125-1134.	0.8	28
20	Nanoemulsions as Delivery Systems for Poly-Chemotherapy Aiming at Melanoma Treatment. <i>Cancers</i> , 2020, 12, 1198.	3.7	25
21	Anti-cytokine autoantibodies in autoimmune diseases. <i>American Journal of Clinical and Experimental Immunology</i> , 2012, 1, 136-46.	0.2	25
22	Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. <i>British Journal of Haematology</i> , 2021, 193, 386-396.	2.5	23
23	Differential induction of IL-17, IL-10, and IL-9 in human T helper cells by B7h and B7.1. <i>Cytokine</i> , 2013, 64, 322-330.	3.2	22
24	Variations of the UNC13D Gene in Patients with Autoimmune Lymphoproliferative Syndrome. <i>PLoS ONE</i> , 2013, 8, e68045.	2.5	20
25	Platelets: "multiple choice" effectors in the immune response and their implication in COVID-19 thromboinflammatory process. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 895-906.	1.3	19
26	A double blind randomized experimental study on the use of IgM-enriched polyclonal immunoglobulins in an animal model of pneumonia developing shock. <i>Immunobiology</i> , 2017, 222, 1074-1080.	1.9	18
27	Sr-Containing Mesoporous Bioactive Glasses Bio-Functionalized with Recombinant ICOS-Fc: An In Vitro Study. <i>Nanomaterials</i> , 2021, 11, 321.	4.1	17
28	Mutation of <i>FAS</i> , <i>XIAP</i> , and <i>UNC13D</i> Genes in a Patient With a Complex Lymphoproliferative Phenotype. <i>Pediatrics</i> , 2013, 132, e1052-e1058.	2.1	16
29	The Gut-Brain-Immune Axis in Autism Spectrum Disorders: A State-of-Art Report. <i>Frontiers in Psychiatry</i> , 2021, 12, 755171.	2.6	14
30	Role of tissue inhibitor of metalloproteinases-1 in the development of autoimmune lymphoproliferation. <i>Haematologica</i> , 2010, 95, 1897-1904.	3.5	11
31	Inducible T-Cell Costimulator Mediates Lymphocyte/Macrophage Interactions During Liver Repair. <i>Frontiers in Immunology</i> , 2021, 12, 786680.	4.8	11
32	The -346T polymorphism of the SH2D1A gene is a risk factor for development of autoimmunity/lymphoproliferation in males with defective Fas function. <i>Human Immunology</i> , 2012, 73, 585-592.	2.4	9
33	Vitamin D Supplementation Modulates ICOS+ and ICOS ^{hi} Regulatory T Cell in Siblings of Children With Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4767-e4777.	3.6	9
34	Inducible T-Cell Costimulator Ligand Plays a Dual Role in Melanoma Metastasis upon Binding to Osteopontin or Inducible T-Cell Costimulator. <i>Biomedicines</i> , 2022, 10, 51.	3.2	9
35	A mutation in caspase-9 decreases the expression of BAFFR and ICOS in patients with immunodeficiency and lymphoproliferation. <i>Genes and Immunity</i> , 2015, 16, 151-161.	4.1	8
36	Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia. <i>British Journal of Haematology</i> , 2017, 176, 258-267.	2.5	8

#	ARTICLE	IF	CITATIONS
37	Anti-Asparaginase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity. <i>Hematological Oncology</i> , 2020, 38, 204-206.	1.7	6
38	Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple myeloma microenvironment. <i>British Journal of Haematology</i> , 2022, 196, 1369-1380.	2.5	6
39	ICOSL Stimulation by ICOS-Fc Accelerates Cutaneous Wound Healing In Vivo. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7363.	4.1	6
40	Genomic and functional evaluation of TNFSF14 in multiple sclerosis susceptibility. <i>Journal of Genetics and Genomics</i> , 2021, 48, 497-507.	3.9	3
41	Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study). <i>Blood</i> , 2018, 132, 1135-1135.	1.4	3
42	Evaluation of Serum Levels of Osteopontin and IgG Anti-Osteopontin Autoantibodies As Potential Biomarkers of Immune Activation in Patients with Allergic Diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB394.	2.9	0
43	Immunogenetic Characterization of Primary Immune Thrombocytopenia (ITP) in Adults: Preliminary Results of the Unit Study.. <i>Blood</i> , 2012, 120, 2192-2192.	1.4	0
44	Immunogenetic Characterization of Primary Immune Thrombocytopenia (ITP) in Adults: Results of the Unit Study. <i>Blood</i> , 2014, 124, 1461-1461.	1.4	0